KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~ Phase 2b dose range finding study showed rapid and highly significant [...]
Dr Mary Kerr, CEO of KaNDy Therapeutics to present at Women’s Health Innovation Summit, Boston
In December (3rd-4th, 2019) 150 leaders in women’s health will be coming together in Boston at the Women’s Health Innovation Summit to drive innovation at the convergence of technology and [...]
Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the 25th Annual BIO-Europe Conference
Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the 25th Annual BIO-Europe Conference During the BIO-Europe conference taking place from 11-13 November in Hamburg, Dr Mary Kerr will be [...]
Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the SVB Leerink New Treatments Focused on Women’s Health Conference, New York
Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the SVB Leerink New Treatments Focused on Women’s Health Conference, New York On the 10 October, Dr Mary Kerr will be attending and [...]
